FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911986426> ?p ?o ?g. }

• W2911986426 endingPage "4321" @default.
• W2911986426 startingPage "4321" @default.
• W2911986426 abstract "Abstract In myeloproliferative neoplasms (MPN), somatic mutations in recurrently mutated myeloid leukemia genes, apart from MPN driver genes, are common and can increase transformation risk to acute myeloid leukemia (AML). However, the temporal acquisition of these mutations, the properties of the cells bearing these mutations, and how each mutation cooperates to promote leukemic transformation remains largely unknown. We therefore examined blood and bone marrow samples collected serially from patients with myelofibrosis (MF) who developed AML to further elucidate the genetic basis of leukemic transformation. Specific aims include: 1) determining the timeline of acquisition of mutations that contribute to AML in chronic phase and 2) defining the cell type that harbours the clone fated to initiate AML. Ten patients who transformed to AML following a diagnosis of MF (6 PMF, 3 post-PV MF, 1 post-ET MF) were studied. The time interval from the first MPN collection to AML diagnosis ranged between 1.5 to 6.6 years; and in 4 patients additional MPN samples collected between these time points were available for study. Somatic mutations were identified from whole genome sequencing (WGS) data of AML blasts (CD45dim cells), the MPN clone (CD45highCD33+ and CD34+ cells), and germline references (T-cells or Buccal DNA); and from targeted sequencing results of 54 recurrently mutated myeloid leukemia genes performed on AML samples as part of another study. Stem and progenitor populations (HSC, MPP, LMPP, CMP, MEP, GMP), as well as, mature cell populations (myeloid, erythroid, T-lymphoid, B-lymphoid and NK) were sorted from MPN time points and whole genome amplified using the REPLI-g Single Cell Kit (Qiagen). Somatic mutations were tracked by droplet digital PCR (ddPCR) and/or targeted sequencing. We identified an average of 5 (range 1-8) recurrently mutated myeloid leukemia genes that were somatically mutated in each patient at AML diagnosis, with an average of 5.5 (range 1-11) different mutations affecting these genes. Many of these mutations were present at ≥5% variant allele frequency (VAF) in the MPN clone at the earliest chronic phase time point. In 8 patients, the MPN driver mutation was detected in the MPN clone and AML blasts (MPNdriver-concordant), while in 2 other patients there was discordance as JAK2V617F was present in the MPN clone, but not the AML blasts. Myeloid leukemia genes that were mutated in 2 or more patients included SRSF2 (n=5), ASXL1 (n=4), TET2 (n=4), IDH1/2 (n=4), RUNX1 (n=4), NRAS (n=4), KRAS (n=2), U2AF1 (n=2), PHF6 (n=2), and STAG2 (n=2). We tracked mutations by ddPCR in populations sorted from MPN time points and demonstrated that 10 out of 13 mutations not identified by WGS were in fact present at low VAF in one or more cell populations. Moreover, in 5 patients with MPNdriver-concordant AML, the AML-fated clone was detectable 1.5 to 3 years before AML was diagnosed; and in 4 of these patients the AML-fated clone resided among cells with a HSC or MPP immunophenotype. In order to better establish the reservoir harbouring AML-fated clones, clonal tracking within the stem and progenitor populations by targeted sequencing of a greater number of AML-specific variants is underway. Among the two patients with JAK2V617F-negative AML, we observed in one patient the emergence of the AML-fated clone within one year of AML diagnosis. In summary, we show that clones fated to intiate AML in patients with MF often reside among cells with a HSC or MPP immunophenotype and can appear several years prior to the diagnosis of AML. This strongly suggests that mechanisms beyond the acquisition of somatic driver mutations (including but not limited to epigenetic alterations, acquisition of non-coding mutations, inflammation) are necessary to effectively promote full leukemic transformation. Interestingly, in one patient with JAK2V617F-negative AML (following JAK2V617F-positive MF), the latency period between the appearance of the AML-fated clone and AML diagnosis was much shorter, suggesting that the mechanisms underlying transformation are likely different for these 2 clonal evolutionary pathways. Disclosures Gupta: Novartis: Consultancy, Honoraria, Research Funding; Incyte: Research Funding." @default.
• W2911986426 created "2019-02-21" @default.
• W2911986426 creator A5014738261 @default.
• W2911986426 creator A5026397928 @default.
• W2911986426 creator A5028838867 @default.
• W2911986426 creator A5031785087 @default.
• W2911986426 creator A5042576332 @default.
• W2911986426 creator A5058235020 @default.
• W2911986426 creator A5062585255 @default.
• W2911986426 creator A5067214379 @default.
• W2911986426 creator A5081082257 @default.
• W2911986426 creator A5081740092 @default.
• W2911986426 creator A5083780768 @default.
• W2911986426 creator A5086539748 @default.
• W2911986426 creator A5090356933 @default.
• W2911986426 date "2018-11-29" @default.
• W2911986426 modified "2023-09-27" @default.
• W2911986426 title "AML-Fated Clones Arise in Stem and Progenitor Cells in Myelofibrosis Patients Several Years Prior to AML Diagnosis" @default.
• W2911986426 doi "https://doi.org/10.1182/blood-2018-99-118889" @default.
• W2911986426 hasPublicationYear "2018" @default.
• W2911986426 type Work @default.
• W2911986426 sameAs 2911986426 @default.
• W2911986426 citedByCount "0" @default.
• W2911986426 crossrefType "journal-article" @default.
• W2911986426 hasAuthorship W2911986426A5014738261 @default.
• W2911986426 hasAuthorship W2911986426A5026397928 @default.
• W2911986426 hasAuthorship W2911986426A5028838867 @default.
• W2911986426 hasAuthorship W2911986426A5031785087 @default.
• W2911986426 hasAuthorship W2911986426A5042576332 @default.
• W2911986426 hasAuthorship W2911986426A5058235020 @default.
• W2911986426 hasAuthorship W2911986426A5062585255 @default.
• W2911986426 hasAuthorship W2911986426A5067214379 @default.
• W2911986426 hasAuthorship W2911986426A5081082257 @default.
• W2911986426 hasAuthorship W2911986426A5081740092 @default.
• W2911986426 hasAuthorship W2911986426A5083780768 @default.
• W2911986426 hasAuthorship W2911986426A5086539748 @default.
• W2911986426 hasAuthorship W2911986426A5090356933 @default.
• W2911986426 hasConcept C10205521 @default.
• W2911986426 hasConcept C104317684 @default.
• W2911986426 hasConcept C203014093 @default.
• W2911986426 hasConcept C2778729363 @default.
• W2911986426 hasConcept C2779282312 @default.
• W2911986426 hasConcept C2780007613 @default.
• W2911986426 hasConcept C2780076729 @default.
• W2911986426 hasConcept C28328180 @default.
• W2911986426 hasConcept C502942594 @default.
• W2911986426 hasConcept C54355233 @default.
• W2911986426 hasConcept C81089528 @default.
• W2911986426 hasConcept C86803240 @default.
• W2911986426 hasConceptScore W2911986426C10205521 @default.
• W2911986426 hasConceptScore W2911986426C104317684 @default.
• W2911986426 hasConceptScore W2911986426C203014093 @default.
• W2911986426 hasConceptScore W2911986426C2778729363 @default.
• W2911986426 hasConceptScore W2911986426C2779282312 @default.
• W2911986426 hasConceptScore W2911986426C2780007613 @default.
• W2911986426 hasConceptScore W2911986426C2780076729 @default.
• W2911986426 hasConceptScore W2911986426C28328180 @default.
• W2911986426 hasConceptScore W2911986426C502942594 @default.
• W2911986426 hasConceptScore W2911986426C54355233 @default.
• W2911986426 hasConceptScore W2911986426C81089528 @default.
• W2911986426 hasConceptScore W2911986426C86803240 @default.
• W2911986426 hasIssue "Supplement 1" @default.
• W2911986426 hasLocation W29119864261 @default.
• W2911986426 hasOpenAccess W2911986426 @default.
• W2911986426 hasPrimaryLocation W29119864261 @default.
• W2911986426 hasRelatedWork W2000367099 @default.
• W2911986426 hasRelatedWork W2169470737 @default.
• W2911986426 hasRelatedWork W2236712884 @default.
• W2911986426 hasRelatedWork W2372009164 @default.
• W2911986426 hasRelatedWork W2410107327 @default.
• W2911986426 hasRelatedWork W2979668228 @default.
• W2911986426 hasRelatedWork W4230359604 @default.
• W2911986426 hasRelatedWork W4233417895 @default.
• W2911986426 hasRelatedWork W4240949613 @default.
• W2911986426 hasRelatedWork W4243856164 @default.
• W2911986426 hasVolume "132" @default.
• W2911986426 isParatext "false" @default.
• W2911986426 isRetracted "false" @default.
• W2911986426 magId "2911986426" @default.
• W2911986426 workType "article" @default.